Amedisys, Inc. (NASDAQ:AMED) Sees Large Drop in Short Interest

Amedisys, Inc. (NASDAQ:AMED) was the recipient of a significant decline in short interest during the month of July. As of July 15th, there was short interest totalling 1,980,000 shares, a decline of 14.3% from the June 30th total of 2,310,000 shares. Based on an average trading volume of 351,100 shares, the short-interest ratio is currently 5.6 days. Currently, 6.2% of the shares of the stock are sold short.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. William Blair lowered Amedisys from an “outperform” rating to a “market perform” rating in a research note on Monday, July 1st. StockNews.com upgraded Amedisys from a “hold” rating to a “buy” rating in a research report on Saturday, May 4th. Deutsche Bank Aktiengesellschaft downgraded Amedisys from a “buy” rating to a “hold” rating and set a $101.00 price objective on the stock. in a research report on Monday. Finally, Cantor Fitzgerald reiterated a “neutral” rating and set a $101.00 price objective on shares of Amedisys in a research report on Thursday, July 25th. Five investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, Amedisys currently has an average rating of “Hold” and an average price target of $100.75.

Amedisys Stock Performance

Shares of Amedisys stock opened at $98.05 on Wednesday. Amedisys has a one year low of $89.55 and a one year high of $98.95. The company has a debt-to-equity ratio of 0.30, a quick ratio of 1.16 and a current ratio of 1.16. The company has a market cap of $3.21 billion, a price-to-earnings ratio of -153.20, a PEG ratio of 2.25 and a beta of 0.79. The business’s 50 day moving average price is $94.96 and its 200 day moving average price is $93.88.

Institutional Investors Weigh In On Amedisys

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Banque Cantonale Vaudoise purchased a new stake in Amedisys in the first quarter valued at $60,000. Innealta Capital LLC purchased a new stake in Amedisys in the second quarter valued at $64,000. Covestor Ltd raised its position in Amedisys by 134.2% in the first quarter. Covestor Ltd now owns 780 shares of the health services provider’s stock valued at $72,000 after purchasing an additional 447 shares during the period. Signaturefd LLC raised its position in Amedisys by 88.2% in the second quarter. Signaturefd LLC now owns 1,131 shares of the health services provider’s stock valued at $104,000 after purchasing an additional 530 shares during the period. Finally, Cetera Trust Company N.A purchased a new stake in Amedisys in the fourth quarter valued at $215,000. Hedge funds and other institutional investors own 94.36% of the company’s stock.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.